+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Multi-phase therapy of multiple myeloma using high-dose busulfan, melphalan and cyclophosphamide followed by autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging



Multi-phase therapy of multiple myeloma using high-dose busulfan, melphalan and cyclophosphamide followed by autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging



Blood 82(10 Suppl. 1): 266A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 032441048

Download citation: RISBibTeXText


Related references

High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leukemia Research 31(8): 1069-1075, 2006

High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67(5): 1298-1301, 1986

VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma. Bone Marrow Transplantation 4(Suppl. 4): 109-112, 1989

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation 22(8): 1391-1396, 2018

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma. Blood Research 53(2): 105-109, 2018

High dose melphalan hdm as in vivo purging before autologous transplantation in multiple myeloma mm. Bone Marrow Transplantation 5(Suppl. 2): 95, 1990

High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. Journal of Clinical Oncology 4(12): 1804-1810, 1986

High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone: 27-32, Y 1, 1998

Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biology of Blood and Marrow Transplantation 13(12): 1448-1454, 2007

4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. Journal of Clinical Oncology 9(1): 85-93, 1991

Colony stimulating activity in the serum of patients with multiple myeloma is enhanced by interleukin 3 a possible role for interleukin 3 after high dose melphalan and autologous bone marrow transplantation for multiple myeloma. British Journal of Haematology 75(3): 366-372, 1990

Feasibility of high dose busulfan and melphalan with autologous hematopoietic stem cell transplantation in multiple myeloma. Blood 90(10 Suppl. 1 Part 2): 355B, Nov 15, 1997

Survival and toxicity update following tandem cycle high-dose melphalan and busulfan/cyclophosphamide with autologous peripheral blood progenitor cell rescue in multiple myeloma lack of correlation between the incidence of hepatic veno-occlusive disease and busulfan pharmacokinetics. Blood 92(10 Suppl. 1 Part 1-2): 373B, Nov 15, 1998

High dose melphalan hdm and autologous bone marrow transplantation abmt followed by immunotherapy with interleukin 2 il 2 alpha interferon in patients with multiple myeloma mm. Experimental Hematology 19(6): 559, 1991

The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's Hospital studies. Hematological Oncology 6(2): 173-179, 1988